Neurotrophic approach in preventive therapy of alzheimer disease

2011 ◽  
Vol 26 (S2) ◽  
pp. 488-488
Author(s):  
S. Gavrilova ◽  
I. Kolykhalov ◽  
Y. Fedorova ◽  
M. Odinak ◽  
A. Emelin ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Alzheimer Disease ◽  
Cognitive Deficit ◽  
Diagnostic Category ◽  
Preventive Therapy ◽  
Long Term Effects ◽  
Clinical Scales ◽  
Slowing Down ◽  
Ad Therapy

IntroductionDuring the last years a great number of new facts of involving nerve growth factors (NGF) in pathogenesis of Alzheimer Disease (AD) and other neurodegenerative diseases have been received. Discovery of neurotrophic effects of Cerebrolysin similar to NGF attracted new attention to it (Rockenstein E. et al. 2000).Clinical study of long-term effects of Cerebrolysin has proved that Cerebrolysin has positive modifying action on the dementia progression (Gavrilova S.I. et al., 2003). That's why we suggest that Cerebrolysin may prevent or slow down clinical manifestation of dementia in patients with mild cognitive impairment (MCI) of amnestic type.The aim of the present study was to investigate in an open comparative prospective clinical trial ability of Cerebrolysin to slow down or prevent transition of MCI syndrome into the clinically evident AD in 2 groups of patients repeatedly treated with 1 month courses of Cerebrolysin or Cavinton during a period of 3 years.Methods110 patients who met the diagnostic criteria of MCI of amnestic typewere included. During the clinical trial patients were assessed with a set of clinical scales and a battery of neuropsychological cognitive tests. Genotyping for the APOE polymorphism was performed as well.ResultsThe superiority of Cerebrolysin over Cavinton in slowing down of the cognitive deficit progression and delaying the time or transition of MCI patients to the diagnostic category of Alzheimer disease during 3 years was demonstrated. Cerebrolysin was particularly effective in MCI patients with the ApoE4 (+) genotype.ConclusionCerebrolysin could be recommended as a preventive AD therapy.

The Immediate And Long-Term Effects of Shexiang Tongxin Dropping Pill On Coronary Slow Flow: Study Protocol For A Randomized Double-Blind Placebo-Controlled Trial

2021 ◽  
Author(s):  
Birong Liu ◽  
Yong Liu ◽  
Liyong Ma ◽  
Jia Liu ◽  
Jingen Li ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Blood Flow ◽  
Blood Stasis ◽  
Blood Stasis Syndrome ◽  
Controlled Study ◽  
Slow Flow ◽  
Long Term Effects ◽  
Coagulation Function ◽  
Coronary Slow Flow

Abstract Background: Coronary slow flow (CSF) is a phenomenon characterized by delayed contrast medium progression in angiography in the absence of obstructive coronary epicardial disease. However, there is currently no definite effective therapy. A small sample self-controlled study had suggested an immediate improvement in coronary slow blood flow by Shexiang Tongxin Dropping Pills (STDP). But high-quality evidences on drug dosage, medication cycle and long-term effects are still lacking while the mechanism of STDP remains unclear. Methods: This study is a randomized, double-blinded, and placebo-controlled clinical trial. A total of 64 CSF patients diagnosed by coronary angiography will be randomly allocated into the test group, using STDP, and the control group, using placebo. The main efficacy indicators for immediate effects include thrombolysis in myocardial infarction (TIMI) blood flow grading and corrected TIMI frame count. Long-term effects will be evaluated by the comparison of cardiac radionuclide score, and patient condition such as angina readmission rate and angina scale. The safety indicators include a routine complete blood count, liver and renal function test, cardiac markers (including TnI, CK-MB, Myo), NT-proBNP, coagulation function, 12-lead electrocardiogram, and echocardiography. All adverse events during the trial will be recorded. Moreover, endothelial factors (including ET-1, NO, eNOS, iNOS), inflammatory factors (including adropin, IL-6, IL-1, IL-18, TNF-α, Lp-PLA2, hs-CRP) will be observed. Blood stasis syndrome (including platelet activation factors such as CD62 and CD63, coagulation function and blood stasis syndrome score) will be evaluated.Trial registration: Chinese Clinical Trial Registry, ChiCTR2000035167. Registered on August 2, 2020. http://www.chictr.org.cn/showproj.aspx?proj=57349

scholarly journals Short- and long-term effects of exercise on neck muscle function in cervical radiculopathy: A randomized clinical trial

2016 ◽  
Vol 25 ◽  
pp. e72
Author(s):  
M. Halvorsen ◽  
D. Falla ◽  
L. Gizzi ◽  
K. Harms-Ringdahl ◽  
A. Peolsson ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Muscle Function ◽  
Cervical Radiculopathy ◽  
Neck Muscle ◽  
Long Term Effects ◽  
Short And Long Term

scholarly journals LONG-TERM EFFECTS OF EPIRUBICIN ON INCIDENCE OF HEART FAILURE IN WOMEN WITH BREAST CANCER: DATA FROM A RANDOMIZED CLINICAL TRIAL

2016 ◽  
Vol 67 (13) ◽  
pp. 1513
Author(s):  
Ann Bøcher Secher Banke ◽  
Emil Fosbol ◽  
Jacob Møller ◽  
Gunnar Gislason ◽  
Mads Andersen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Heart Failure ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Breast Cancer Data ◽  
Long Term Effects ◽  
Cancer Data

scholarly journals Effects of Including Information about Hidden Hearing Loss in an Adopt-A-Band Program on College Band Members' Attitudes toward Healthy Hearing Behaviors

2018 ◽  
Vol 39 (02) ◽  
pp. 210-220 ◽  
Author(s):  
Carole Johnson ◽  
Jonathan Baldwin ◽  
Jeffrey Danhauer ◽  
Brian Wolfe ◽  
Stevana Jeannont ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Hearing Loss ◽  
Confidence Interval ◽  
Self Efficacy ◽  
Future Research ◽  
Long Term Effects ◽  
Marching Bands ◽  
Hidden Hearing Loss ◽  
College Band

AbstractYoung musicians may be at risk for developing cochlear synaptopathy (CS), or hidden hearing loss (HHL), that could lead to permanent music-induced hearing loss (MIHL). Patients with CS often complain of tinnitus and/or difficulty understanding speech in noisy situations, even though traditional audiometric testing indicates normal hearing. The aim of this article was to determine the effects of including information about HHL on an Adopt-A-Band program involving college band members' concern about and self-efficacy toward the prevention of MIHL. We conducted a single-blinded, randomized clinical trial. Forty-eight band members participated in this study. Band members were randomly assigned to two Adopt-A-Band presentations, one with and one without information on HHL. Including information about HHL had no effect on these band members' concerns about and self-efficacy toward the prevention of MIHL. However, the Adopt-A-Band program resulted in significantly increased concern for MIHL by 39.5% (p < 0.0001, 95% confidence interval [CI]: 25–54.2), self-efficacy in its prevention by 79.1% (p < 0.0001, 95% CI: 66.9–91.2), and plans to use musicians' earplugs while playing by 67.4% (p < 0.0001, 95% CI: 53.4–81.45). Although inclusion of information about HHL did not have a significant effect, the Adopt-A-Band program, in general, significantly increased the immediate intent of these students to practice healthy hearing behaviors. Future research is needed to determine the long-term effects of using the Adopt-A-Band program with university marching bands' use of healthy hearing behaviors.

scholarly journals Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

2009 ◽  
Vol 80 (6) ◽  
pp. 600-607 ◽  
Author(s):  
O L Lopez ◽  
J T Becker ◽  
A S Wahed ◽  
J Saxton ◽  
R A Sweet ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Cholinesterase Inhibition ◽  
Long Term Effects

scholarly journals Cardiac Effects of Anticancer Therapy in the Elderly

2014 ◽  
Vol 32 (24) ◽  
pp. 2654-2661 ◽  
Author(s):  
Melissa K. Accordino ◽  
Alfred I. Neugut ◽  
Dawn L. Hershman
Keyword(s):  
Clinical Trial ◽  
Elderly Patients ◽  
Clinical Trial Data ◽  
The Elderly ◽  
Cardiac Risk ◽  
Long Term Effects ◽  
Cardiac Events ◽  
Long Term Follow Up ◽  
Clinical Trial Evidence

Cancer incidence increases with age, and as life expectancy increases, the number of elderly patients with cancer is increasing. Cancer treatments, including chemotherapy and radiotherapy, have significant short- and long-term effects on cardiovascular function. These cardiotoxic effects can be acute, such as changes in electrocardiogram (ECG), arrhythmias, ischemia, and pericarditis and/or myocarditis-like syndromes, or they can be chronic, such as ventricular dysfunction. Anticancer therapies can also have indirect effects, such as alterations in blood pressure, or can cause metabolic abnormalities that subsequently increase risk for cardiac events. In this review, we explore both observational and clinical trial evidence of cardiac risk in the elderly. In both observational and clinical trial data, risk of cardiotoxicity with anthracycline-based chemotherapy increases with age. However, it is less clear whether the association between age and cardiotoxicity exists for newer treatments. The association may not be well demonstrated as a result of under-representation of elderly patients in clinical trials and avoidance of these therapies in this population. In addition, we discuss strategies for surveillance and prevention of cardiotoxicity in the elderly. In the elderly, it is important to be aware of the potential for cardiotoxicity during long-term follow-up and to consider both prevention and surveillance of these late effects.

scholarly journals The Kansas University DHA Outcomes Study (KUDOS) clinical trial: long-term behavioral follow-up of the effects of prenatal DHA supplementation

2019 ◽  
Vol 109 (5) ◽  
pp. 1380-1392 ◽  
Author(s):  
John Colombo ◽  
D Jill Shaddy ◽  
Kathleen Gustafson ◽  
Byron J Gajewski ◽  
Jocelynn M Thodosoff ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Preterm Birth ◽  
Visual Attention ◽  
Maternal Blood ◽  
Chain Polyunsaturated Fatty Acid ◽  
Long Term Effects ◽  
Double Blind ◽  
Early Preterm Birth

ABSTRACT Background Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid that has been linked to improved vision and cognition in postnatal feeding studies and has been consistently associated with reduction of early preterm birth in prenatal supplementation trials. This is a report of the first long-term follow-up of infants from mothers receiving prenatal DHA supplementation in a US cohort. Objective Our objective was to evaluate the efficacy of the prenatal supplementation on both global and granular longitudinal assessments of cognitive and behavioral development. Methods In a randomized double-blind clinical trial, mothers received either 600 mg/d of DHA or a placebo beginning at 14.5 weeks of gestation and capsules were provided until delivery. Children from those pregnancies were followed by cognitive and behavioral assessments administered from 10 mo through 6 y of age. From 301 mothers in the initial study, ∼200 infants completed the longitudinal schedule. Results Although this intervention had been shown to reduce high-risk pregnancies and improve visual attention in infants during the first year, only a few positive long-term effects of prenatal DHA supplementation emerged from analyses of this follow-up. Increases in maternal blood DHA during pregnancy were related to verbal and full scale intelligence quotient (IQ) scores at 5 and 6 y, but these effects disappeared after controlling for SES. Maternal blood DHA concentrations at delivery were unrelated to outcomes, although maternal DHA at enrollment was related to productive vocabulary at 18 mo. Conclusions Although prenatal DHA supplementation substantially reduced early preterm birth and improved visual attention in infancy in this sample, no consistent long-term benefits were observed into childhood. Increases in maternal blood DHA concentration in pregnancy were related to higher IQs but this effect was confounded with SES and disappeared when SES was statistically controlled. This trial was registered at http://www.clinicaltrials.gov as NCT00266825 and NCT02487771.

Sign in / Sign up

Export Citation Format

Share Document